SCHEMBL340043

SCHEMBL340043

CCCCCCCCCCCC=C1CCC(OCCOP(=O)(O)OCC[N+]2(C)CCCCC2)CC1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.36
LPAR3 Q9UBY5 5/20 0.32
P2RY10 O00398 1/20 0.32
TERT O14746 1/20 0.32
UCHL3 P15374 1/20 0.32
AKT1 P31749 1/20 0.32
MAPK14 Q16539 1/20 0.32
LPAR1 Q92633 3/20 0.32
LPAR2 Q9HBW0 3/20 0.32
SGPL1 O95470 3/20 0.31
S1PR1 P21453 2/20 0.31
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
APOBEC3A P31941 1/20 0.30
APOBEC3G Q9HC16 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339933 1.00 CDC25A (0.36) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL338952 1.00 CDC25A (0.36) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL339734 0.90 LPAR3 (0.32) LPAR3P2RY10LPAR1LPAR2SGPL1
SCHEMBL339932 0.85 CDC25A (0.34) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL338951 0.85 CDC25A (0.34) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL340042 0.85 CDC25A (0.34) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL339476 0.85 CDC25A (0.44) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL338753 0.85 CDC25A (0.44) CDC25ALPAR3P2RY10TERTUCHL3
SCHEMBL5663655 0.83 LPAR3 (0.36) LPAR3P2RY10LPAR1LPAR2SGPL1
SCHEMBL5673069 0.82 FABP3 (0.41) CDC25ALPAR3AKT1S1PR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097752-B2 Antiprotozoal ring-substituted phospholipids MAKSCIENTIFIC, LLC (US) 2012-01-17 US claimed
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids MAK SCIENTIFIC CORPORATION (US) 2006-05-18 US claimed
US-8097752-B2 Antiprotozoal ring-substituted phospholipids MAKSCIENTIFIC, LLC (US) 2012-01-17 US disclosed
EP-1578754-A4 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS MAKSCIENTIFIC LLC (US) 2006-07-19 EP disclosed
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids MAK SCIENTIFIC CORPORATION (US) 2006-05-18 US disclosed
EP-1578754-A2 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS MakScientific Corporation (US) 2005-09-28 EP disclosed
WO-2004041167-A2 ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS CALOGEROPOULOU THEODORA (GR) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060105998-A1 Antiprotozoal ring-substiuted phospholipids PHOSPHO1, PLTP, PLA2G2C CDC25A 957/4885LPAR3 109/4885P2RY10 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.